Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptome analysis of differentially expressed genes by tryptophanyl-tRNA synthetase 1 in human peripheral blood mononuclear cells

ABSTRACT: Tryptophanyl tRNA synthetase 1 (WARS1) is classically known as an essential housekeeping enzyme that ligates tryptophan to its cognate tRNA for protein synthesis. Interestingly, in the presence of pathogenic infection, WARS1 is immediately released from monocytes into the extracellular space. Secreted WARS1 promotes the innate inflammatory response by activating toll-like receptor (TLR) 2 and TLR4/myeloid differentiation factor-2 (MD-2) signaling. The purpose of this study was to investigate the expression profile of genes associated with the inflammatory response in WARS1-stimulated human peripheral blood mononuclear cells (PBMCs). As a result, WARS1 significantly upregulated the expression of genes associated with TREM1, IL-8, and IL-6 signaling in PBMCs.

ORGANISM(S): Homo sapiens

PROVIDER: GSE243125 | GEO | 2023/09/22

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gel LC-MS/MS analyses of MMP cleavage of tryptophanyl-tRNA synthetase

Project description:Tryptophanyl-tRNA synthetase was incubated by MMPs, cleavage products were resolved on SDS-PAGE. Cleavage products were trypsin digested and analyzed by LC-MS/MS.

2019-05-29 | PXD013217 | Pride

Secreted tryptophanyl-tRNA synthetase levels predict severe systemic and neurological toxicities following CAR T therapy [Patient_sample_RNAseq]

Project description:CAR T therapy is constrained by life-threatening cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), interrelated toxicities with poorly defined upstream triggers. While both toxicities involve aberrant myeloid activation, their shared initial drivers remain elusive. Through proteomic profiling of patient samples, we identified secreted tryptophanyl-tRNA synthetase (WRS) as a key signature of these adverse events. Cohort analyses reveal plasma WRS as a biomarker for high-grade toxicities. Mechanistically, aggregated WRS, not the diffused form, is pathogenic under the low-sodium microenvironment. Aggregated WRS was detected in both the plasma and central nervous system under pathological conditions, and functionally validated as a potential driver of both toxicities. Therapeutically targeting the WRS circuit in humanized mouse models attenuates both systemic and neurological toxicities. Our bedside-to-bench investigative pipeline establishes WRS as a molecular nexus linking CRS and neurotoxicity, offering an integrated strategy to improve CAR T treatment safety.

2026-09-02 | GSE307358 | GEO

Secreted tryptophanyl-tRNA synthetase levels predict severe systemic and neurological toxicities following CAR T therapy [TLR2_knockdown_monocyte_RNAseq]

2026-09-02 | GSE307357 | GEO

Secreted tryptophanyl-tRNA synthetase levels predict severe systemic and neurological toxicities following CAR T therapy [Human_monocyte_RNAseq]

2026-09-02 | GSE307356 | GEO

Secreted tryptophanyl-tRNA synthetase levels predict severe systemic and neurological toxicities following CAR T therapy [Patient_sample_RNAseq]

Project description:Secreted tryptophanyl-tRNA synthetase levels predict severe systemic and neurological toxicities following CAR T therapy [Patient_sample_RNAseq]

| PRJNA1316348 | ENA

Secreted tryptophanyl-tRNA synthetase levels predict severe systemic and neurological toxicities following CAR T therapy [Human_monocyte_RNAseq]

Project description:Secreted tryptophanyl-tRNA synthetase levels predict severe systemic and neurological toxicities following CAR T therapy [Human_monocyte_RNAseq]

| PRJNA1316415 | ENA

Secreted tryptophanyl-tRNA synthetase levels predict severe systemic and neurological toxicities following CAR T therapy [TLR2_knockdown_monocyte_RNAseq]

Project description:Secreted tryptophanyl-tRNA synthetase levels predict severe systemic and neurological toxicities following CAR T therapy [TLR2_knockdown_monocyte_RNAseq]

| PRJNA1316330 | ENA

Secreted tryptophanyl-tRNA synthetase levels predict severe systemic and neurological toxicities following CAR T therapy

Project description:CAR T therapy is constrained by life-threatening cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), interrelated toxicities with poorly defined upstream triggers. While both toxicities involve aberrant myeloid activation, their shared initial drivers remain elusive. Through proteomic profiling of patient samples, we identified secreted tryptophanyl-tRNA synthetase (WRS) as a key signature of these adverse events. Cohort analyses reveal plasma WRS as a unifying predictive biomarker for both toxicities. Mechanistically, aggregated WRS, not the diffused form, is pathogenic under the low-sodium microenvironment. Aggregated WRS was detected in both the plasma and central nervous system under pathological conditions, and functionally validated as a potential driver of both toxicities. Therapeutically targeting the WRS circuit in humanized mouse models attenuates both systemic and neurological toxicities. Our bedside-to-bench investigative pipeline establishes WRS as a molecular nexus linking CRS and neurotoxicity, offering an integrated strategy to improve CAR T treatment safety.

2026-09-05 | PXD076370 | Pride

Secreted tryptophanyl-tRNA synthetase levels predict severe systemic and neurological toxicities following CAR T therapy

Project description:CAR T therapy is constrained by life-threatening cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), interrelated toxicities with poorly defined upstream triggers. While both toxicities involve aberrant myeloid activation, their shared initial drivers remain elusive. Through proteomic profiling of patient samples, we identified secreted tryptophanyl-tRNA synthetase (WRS) as a key signature of these adverse events. Cohort analyses reveal plasma WRS as a unifying predictive biomarker for both toxicities. Mechanistically, aggregated WRS, not the diffused form, is pathogenic under the low-sodium microenvironment. Aggregated WRS was detected in both the plasma and central nervous system under pathological conditions, and functionally validated as a potential driver of both toxicities. Therapeutically targeting the WRS circuit in humanized mouse models attenuates both systemic and neurological toxicities. Our bedside-to-bench investigative pipeline establishes WRS as a molecular nexus linking CRS and neurotoxicity, offering an integrated strategy to improve CAR T treatment safety.

2026-09-05 | PXD076368 | Pride

Serine-Threonine Kinase Encoded by a Split hipA Homologous Gene of Escherichia coli Inhibits Tryptophanyl-tRNA Synthetase

Project description:Type II toxin – antitoxin modules encode a stable toxin that inhibits translation, replication or cell wall synthesis and an unstable protein antitoxin that neutralizes the toxin by direct protein – protein contact. The hipBA module of Escherichia coli K-12 codes for HipA, a eukaryote-like serine/threonine protein kinase that phosphorylates and inhibits glutamyl-tRNA synthetase. Induction of hipA leads to a reduced level of charged glutamyl tRNA that, in turn, inhibits translation, induces RelA-dependent (p)ppGpp synthesis and multidrug tolerance (persistence). Here, we describe the discovery of a three-component TA module hipBST of E. coli O127:H6 strain E2348/69 that encodes HipT, which exhibits sequence similarity with the C-terminal part of HipA. We show that HipT is a kinase that phosphorylates tryptophanyl-tRNA synthetase in vitro at conserved serine residue. Consistently, induction of hipT inhibits cell growth, stimulates production of stringent factor (p)ppGpp and induces persistence. Remarkably, the gene immediately upstream of hipT, called hipS, encodes a small protein that exhibits sequence similarity with the C-terminal part of HipA. Unexpectedly, HipT kinase is neutralized by HipS in vivo whereas the third component, HipB0127, encoded by the first gene of the operon, does not counteract HipT kinase. However, HipB contains a HTH DNA-binding domain and may function to autoregulate the hipBST operon. Thus, hipA has been split into two genes, hipS and hipT that function as a toxin – antitoxin pair.

2019-06-24 | PXD012023 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data